YOUR BUSINESS AUTHORITY
Springfield, MO
YOUR BUSINESS AUTHORITY
Springfield, MO
When it comes to healthcare, doctors’ options are mostly limited to pharmaceuticals that are already in circulation. For some patients, this simply doesn’t get them to the outcome they need.
In decades past, this meant waiting for new options to hit the market, or worse; living life in pain or discomfort. FDA regulations require that new medicine development is a tedious and lengthy process. New treatments can take years to make it to market.
But there’s a new trend; an in-between option for patients that suffer chronic issues. Phase III and IV medical trials are gaining popularity in SW MO and across the nation.
“Unlike Phase I and II testing, which addresses more critical safety issues, we are testing the overall effectiveness of and continued safety of investigational medicines,” says Ryan Cady, CEO of Clinvest Research. “It’s amazing to see so many people volunteer their time to help advance medicine. We love the time we get to spend with them and it is exciting that many participants experience better results than they’ve received with conventional options.”
Cady has always had a passion for research and a desire to improve healthcare resources in the Ozarks. He assumed ownership of Clinvest in 2016, after his father, Roger Cady, founder of the Headache Center retired.
Since then, he has expanded his focus on the scope of studies they facilitate. “Historically we have been very well known for our work in the migraine and headache industry. We’ve had a hand in working on nearly every new headache medicine that has come to market for the last several years.”
But he says his team’s reputation for accuracy has earned them partnerships with many other types of pharmaceuticals. “We are currently participating in several arthritis and diabetes-related trials and have several more studies on the horizon.”
This expansion has resulted in a positive effect for many: “We’ve had a record year, which is exciting, but we’re most proud of the lives we are impacting both present and future.”
“Drugs do not come to market without the clinical trial process,” says Director of Research Heather Manley. “The participation of Clinvest and our volunteers contribute to the advancement of research. While not everyone is a candidate for every trial,” we keep a database of applicants allowing us to communicate opportunities for new studies to our volunteers.”
You can explore current studies facilitated by Clinvest at Clinvest.com
A safe room and classroom addition at Willard Central Elementary School will be used by the music, arts and athletic programs for a district that had 4,536 students last year, according to Missouri Department of Elementary and Secondary Education figures, but school officials say enrollment is projected to grow.